Description
Dato-DXd is an antibody-drug conjugate (ADC) that combines a monoclonal antibody targeting TROP2 (trophoblast cell-surface antigen 2) with a topoisomerase I inhibitor payload. It is designed to deliver cytotoxic chemotherapy directly to cancer cells that express TROP2, which is found on various solid tumors including breast, lung, and other cancers.
Mechanism of Action
The antibody component binds specifically to TROP2 receptors on cancer cell surfaces, allowing internalization of the conjugate and subsequent release of the topoisomerase I inhibitor payload, which causes DNA damage and cell death.
Side Effects
Fatigue
Nausea
Decreased appetite
Diarrhea
Vomiting
Hair loss
Low white blood cell count
Anemia
And potential interstitial lung disease.
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT06244485
Phase 1
Recruiting
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
United States, China, Italy, Japan
NCT04644068
Phase 1
Active, not recruiting
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
United States, Australia, Canada, China, Czechia, Hungary, Italy, Japan, Poland,